Literature DB >> 16696056

p53 gene alterations and protein accumulation in colorectal cancer.

R Bertorelle1, G Esposito, C Belluco, L Bonaldi, A Del Mistro, D Nitti, M Lise, L Chieco-Bianchi.   

Abstract

Aim-To correlate immunohistochemical staining with single strand conformation polymorphism (SSCP) analysis of the p53 gene in colorectal cancer in order to understand how the findings provided by the two techniques complement each other in defining p53 functional status.Methods-Frozen tumour tissue from 94 patients with colorectal cancer was studied for p53 protein accumulation and gene mutations. Accumulation of p53 protein was detected by immunohistochemistry using PAb1801 and BP53-12-1 monoclonal antibodies. The findings were then compared with SSCP analysis of exons 5 to 8 of the p53 gene. All cases with a positive result by SSCP analysis were confirmed by sequencing.Results-Nuclear staining was observed in 51 (54.2%) cases. SSCP analysis of the DNA amplified by PCR revealed that the electrophoretic pattern had shifted in 30 cases; sequence analysis confirmed the occurrence of a mutation in 29 cases and of a polymorphism in one. In 27 cases both assays gave a positive result, and in 40 both were negative; therefore, concordance between PCR-SSCP and immunohistochemistry was seen in 72% of cases.Conclusion-The data indicate that positive immunostaining corresponds with the presence of a mutation in most, but not all, cases studied; other mechanisms could be responsible for stabilisation and accumulation of p53 protein in the nucleus. Nonsense mutations which do not confer stability on the protein will not be detected by immunohistochemistry and false negative results can also occur with SSCP analysis.

Entities:  

Year:  1996        PMID: 16696056      PMCID: PMC408027          DOI: 10.1136/mp.49.2.m85

Source DB:  PubMed          Journal:  Clin Mol Pathol        ISSN: 1355-2910


  39 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

3.  Polymorphism at codon 213 within the p53 gene.

Authors:  D Carbone; I Chiba; T Mitsudomi
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

4.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.

Authors:  S Levi; A Urbano-Ispizua; R Gill; D M Thomas; J Gilbertson; C Foster; C J Marshall
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation.

Authors:  X Lu; S H Park; T C Thompson; D P Lane
Journal:  Cell       Date:  1992-07-10       Impact factor: 41.582

7.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 9.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  3 in total

1.  p53 and follow-up of colorectal adenocarcinomas.

Authors:  A Polge; J F Bourgaux; E Bancel; C Pignodel; J C Boyer; S Poirey; B M de Bornier; J L Balmes; J P Bali
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

2.  Synchronous Double Bile Duct Cancers with Distinct Genetic Features.

Authors:  Shinichi Morita; Takeshi Suda; Yoji Kishi; Toshimitsu Iwasaki; Nobuyoshi Hiraoka; Itsuo Nagayama; Takahiro Hoshi; Satoshi Abe; Kazuyoshi Yagi; Go Hasegawa; Toshihiko Ikarashi; Shuji Terai
Journal:  Intern Med       Date:  2020-06-02       Impact factor: 1.271

3.  Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Authors:  Theodoros I Roumeliotis; Steven P Williams; Emanuel Gonçalves; Clara Alsinet; Martin Del Castillo Velasco-Herrera; Nanne Aben; Fatemeh Zamanzad Ghavidel; Magali Michaut; Michael Schubert; Stacey Price; James C Wright; Lu Yu; Mi Yang; Rodrigo Dienstmann; Justin Guinney; Pedro Beltrao; Alvis Brazma; Mercedes Pardo; Oliver Stegle; David J Adams; Lodewyk Wessels; Julio Saez-Rodriguez; Ultan McDermott; Jyoti S Choudhary
Journal:  Cell Rep       Date:  2017-08-29       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.